GlassScriptPhysician profile
Kelly Doyle
NPI 1306678990
$2,872.31
in general payments reported to CMS, 2019-2025
36 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $952 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.31 |
| Education | $194.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.06 | 2024-2025 | |
| Incyte Corporation | $323.58 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $288.78 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $226.91 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $156.46 | 2024-2025 | Reblozyl, Opdivo |
| Kite Pharma, INC. | $131.94 | 2025 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $130.57 | 2024-2025 | Iclusig, Alunbrig |
| Pfizer INC. | $127.05 | 2024-2025 | |
| Puma Biotechnology, INC. | $122.11 | 2025 | |
| Genzyme Corporation | $108.82 | 2025 | |
| Daiichi Sankyo INC. | $82.35 | 2024-2025 | Injectafer, Datroway |
| Pharmacosmos Therapeutics INC. | $67.60 | 2024-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $60.05 | 2024-2025 | Xpovio |
| Tersera Therapeutics LLC | $58.26 | 2024-2025 | Zoladex, Quzyttir |
| Jazz Pharmaceuticals INC. | $47.67 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $46.72 | 2024-2025 | Epkinly |
| Servier Pharmaceuticals LLC | $46.64 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $40.38 | 2024-2025 | Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $38.74 | 2025 | |
| Acrotech Biopharma INC. | $34.33 | 2025 | Beleodaq |
| Adc Therapeutics America, INC. | $33.31 | 2024-2025 | |
| Geron Corporation | $30.20 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $29.03 | 2024 | Libtayo |
| Merck Sharp & Dohme LLC | $26.16 | 2025 | Keytruda |
| Sobi, INC | $25.74 | 2024 | |
| Blueprint Medicines Corporation | $24.61 | 2025 | Ayvakit |
| Emd Serono, INC. | $23.52 | 2025 | |
| Celgene Corporation | $23.36 | 2025 | Opdivo |
| Eisai INC. | $22.31 | 2024 | |
| Adaptive Biotechnologies Corporation | $21.82 | 2025 | Clonoseq |
| Astellas Pharma US INC | $20.54 | 2025 | Vyloy |
| Coherus Oncology, INC. | $18.21 | 2025 | Udenyca, Loqtorzi |
| Array Biopharma INC | $17.94 | 2025 | Lorbrena, Braftovi |
| Legend Biotech USA INC. | $17.76 | 2025 | Carvykti |
| Novocure INC. | $17.46 | 2025 | Optune Lua (Novottf-200t) |
| Accord Healthcare, INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.